Track topics on Twitter Track topics that are important to you
Bisphosphonates and denosumab increased bone mineral density in men with nonmetastatic prostate cancer who received androgen deprivation therapy, according to findings published in Annals of Internal Medicine.“Prostate cancer is the most common internal cancer in men and the third most common cause of cancer death in most industrialized countries,” Shabbir M.H. Alibhai, MD, MSc, from the University of Toronto, and colleagues wrote. “Among men with this disease, almost one in two receive androgen deprivation therapy (ADT) at some point after diagnosis. This therapy is associated with many potential adverse effects, including significant bone loss and increased risk for low trauma or fragility fractures similar to that in persons with primary osteoporosis. Although the greatest loss in bone mineral density (BMD) occurs within the first year of ADT use, continued use is associated with ongoing (albeit attenuated) loss in subsequent years along with increased risk for fractures.”
Original Article: Osteoporosis drugs improve bone health for patients with prostate cancerNEXT ARTICLE
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...